Hamrah, Pedram
- Tufts Medical Center · Ophthalmology (investigator's affiliation)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #7,837
- Rising Star
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2010 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$1.2M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#7,837
By linked amount among FY2023 PIs
Earliest Year Loaded
2010
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Hamrah, Pedram as a PI. Multi-PI records show the full award amount for context.
- 5R33NS113341-03R33Contact PIDiscovery of the Biomarker Signature for Neuropathic Corneal PainTufts Medical Center · Ophthalmology (investigator's affiliation)$720.1Kaward amount
- 1R01EY034942-01R01Contact PIThe role of plasmacytoid dendritic cells in corneal immunityTufts Medical Center · Ophthalmology (investigator's affiliation)$507.6Kaward amount
Award organization
Organizations that administered FY2023 awards listing Hamrah, Pedram as a PI.
FY2023 award administered by Tufts Medical Center (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2010First NIH AwardTufts Medical Center
- 2012$500K Cumulative Funding
- 2013$1M Cumulative Funding
- 2014R01 Grant Holder
- 2015$2M Cumulative Funding
- 2016Entered Top 50% NationallyRanked #9515
- 2018$5M Cumulative Funding
- 2019Entered Top 25% NationallyRanked #1453
- 2019Entered Top 10% NationallyRanked #1453
- 2022$10M Cumulative Funding